申请人致力于肥胖、胰岛素抵抗和糖尿病发生的分子免疫学机制研究十余年，在胰岛素抵抗和糖尿病的免疫调节及新药靶发现方面进行了开创性研究。申请人为炎症致胰岛素抵抗的理论提供直接证据，通过NcoR分子调节炎症与改善胰岛素抵抗，并发现炎症致胰岛素抵抗的新机制与新靶点。累计发表学术论文37篇（33篇SCI），申请4项发明专利。主要科研成果以通讯作者或第一作者发表在Cell（2篇）、Nat Med、Cell Metab和PNAS等杂志。迄今，所发表论文被国内外研究者引用达1300多次。申请者已组建研究团队，将继续深入研究肥胖、胰岛素抵抗和糖尿病发生和发展的分子免疫学机制。申请者拟探讨1）巨噬细胞相关信号传导通路调节胰岛素抵抗的作用机制；和 2）肠道核受体抑制子调控胰岛素抵抗的作用机制。在探讨糖尿病发生发展的分子免疫学机制基础上，着力将基础研究的新发现转化为开发防治糖尿病药物新分子药靶和先导化合物的成果。

The proposer has been dedicated to studying the pathogenesis of diabetes for more than 10 years and made breakthrough findings in regarding to the critical role of immune cells and identification of therapeutic targets in inflammation, insulin resistance and diabetes. In total she has published 37 papers and filed 4 patents. As first or corresponding author, the proposer’s papers have been published in several preeminent peer review journals including Cell (2 papers), Nat Med, Cell Metab and PNAS. Her studies have gained considerable attention in the research area and have been cited more than 1300 times by other researchers (as of March 2015). With the strong support by The Institute of Materia Medica, the proposer has built a research team. The proposer and her research group will continue to exploring the molecular cellular mechanisms of obesity, insulin resistance and diabetes, particularly focusing on the roles of the immune system and nuclear receptor co-repressor. The proposed studies will provide new insights into the immunological pathogenesis of insulin resistance and diabetes and identify the therapeutic targets and lead compounds for this disease in the next 3 years.